Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490) Radford, J., Dlugosz-Danecka, M., Connors, J. M., Illes, A., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P., Hutchings, M., Munoz, J., Kim, W., Advani, R., Ansell, S. M., Younes, A., Gallamini, A., Liu, R., Little, M., Fenton, K., Fanale, M., Straus, D. J. WILEY. 2021: 145-147

View details for Web of Science ID 000645412200190